Target-based Virtual Screening of Natural Compounds as Promising Anti-Parkinson’s Agents
Abstract
Background: Parkinson's disease (PD), the second most common neurodegenerative disease among the elderly, is caused by the death of dopaminergic neurons, resulting in dopamine depletion. Monoamine oxidase B (MAO-B) is an important enzyme in PD because it degrades dopamine. Dopamine levels can be elevated by inhibiting MAO-B, especially in the early stages of the disease.
Methods: This study involves virtual screening (docking) of ZINC database natural compounds (N = 200) against MAO-B, followed by ADME and drug-likeness analysis of the top hits.
Results: ZINC899884, ZINC4098705, ZINC14764165, and ZINC18847036 compounds exhibited strong binding to MAO-B and interacted with key MAO-B residues. The Cys172, Ile198, Phe168, Ile199, Leu171, Gln206, Gly58, Tyr326, Leu328, Phe343, Tyr398, Ser59, Tyr60, Gly434, and Tyr435 residues of MAO-B were important in binding with these compounds. In addition, these compounds, like the control Rasagiline, interact with MAO-B via several common residues. Furthermore, ADME and drug-like prediction resulted in promising results, indicating that these compounds have a high gastrointestinal absorption property.
Conclusion: ZINC899884, ZINC4098705, ZINC14764165, and ZINC18847036 can be used as MAO-B inhibitors for PD. However, experimental validation is required to optimize them as MAO-B inhibitors.
Keywords: Drug-likeness; Monoamine oxidase B; Natural compounds; Neurodegenerative disease; Parkinson’s disease
Full Text:
PDFReferences
Van Schependom J, D'Haeseleer M. Advances in neurodegenerative diseases. Journal of Clinical Medicine, (2023); 12(5): 1709.
Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019. Frontiers in Aging Neuroscience, (2022); 14: 937486.
Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neuroscience, (2006); 7(3): 207-219.
Azam F, El-gnidi BA, Alkskas IA, Ahmed MA. Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice. Journal of Enzyme Inhibition and Medicinal Chemistry, (2010); 25(6): 818-826.
Azam F, Ibn-Rajab IA, Alruiad AA. Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships. Pharmazie, (2009); 64(12): 771-795.
Azam F, Alkskas IA, Ahmed MA. Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice. European Journal of Medicinal Chemistry, (2009); 44(10): 3889-3897.
Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends in Neurosciences, (2000); 23(10): 2-7.
Manzoor S, Hoda N. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. European Journal of Medicinal Chemistry, (2020); 206: 112787.
Koszla O, Stepnicki P, Zieba A, Grudzinska A, Matosiuk D, Kaczor AA. Current Approaches and Tools Used in Drug Development against Parkinson's Disease. Biomolecules, (2021); 11(6): 897.
Talevi A. Computer-Aided Drug Design: An Overview. Methods in Molecular Biology, (2018); 1762: 1-19.
Romano JD, Tatonetti NP. Informatics and computational methods in natural product drug discovery: a review and perspectives. Frontiers in Genetics, (2019); 10: 368.
Mushtaq S, Abbasi BH, Uzair B, Abbasi R. Natural products as reservoirs of novel therapeutic agents. EXCLI Journal, (2018); 17: 420-451.
Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nature reviews Drug discovery, (2021); 20(3): 200-216.
Irwin JJ, Shoichet BK. ZINC--a free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling, (2005); 45(1): 177-182.
Schapira M, Abagyan R, Totrov M. Nuclear hormone receptor targeted virtual screening. Journal of Medicinal Chemistry, (2003); 46(14): 3045-3059.
Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. Journal of Molecular Biology, (2004); 337(1): 209-225.
Osterberg F, Morris GM, Sanner MF, Olson AJ, Goodsell DS. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins, (2002); 46(1): 34-40.
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.
van den Heuvel MP, Sporns O. Network hubs in the human brain. Trends in Cognitive Sciences, (2013); 17(12): 683-696.
Merelli A, Czornyj L, Lazarowski A. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Current Pharmaceutical Design, (2013); 19(38): 6791-6801.
Kouli A, Torsney KM, Kuan WL. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. Exon Publications (2018); 3-26.
Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathologica, (2017); 134(2): 187-205.
Alqahtani LS, Alkathiri AS, Alzahrani A, Alghamdi RM, Alamri WA, et al. Structure-Based Virtual Screening of Antiviral Compounds Targeting the Norovirus RdRp Protein. Advancements in Life Sciences, (2024); 11(2): 488-492.
Rafeeq MM, Helmi N, Sain ZM, Iqbal J, Alzahrani A, et al. Target-based virtual screening and molecular dynamics approach to identify potential antileishmanial agents through targeting UvrD-like helicase ATP-binding domain. Advancements in Life Sciences, (2024); 11(1): 237-245.
Alshehri MA, Asiri SA, Alzahrani A, Alazragi RS, Alqahtani LS, et al. Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MMGBSA and MD simulation study. Medical Oncology, (2023); 40(11): 337.
Murad HAS, Rafeeq MM, Alqahtani SM, Rajab BS, Alghamdi S, et al. Molecular docking analysis of AGTR1 antagonists. Bioinformation, (2023); 19(3): 284-289.
Siddiqui MA, Plosker GL. Rasagiline. Drugs Aging, (2005); 22(1): 83-91.
Mohd Sairazi NS, Sirajudeen KNS. Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases. Evidence-Based Complementary and Alternative Medicine, (2020) 6565396.
Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules, (2016); 21(5): 559.
Kennedy DO, Wightman EL. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Advances in Nutrition, (2011); 2(1): 32-50.
DOI: http://dx.doi.org/10.62940/als.v12i2.3592
Refbacks
- There are currently no refbacks.